We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
JBIO
551
Jade Biosciences
JBIO
$1.18B
| $13.4M | 0.02% |
+867,284
| New | +$10.2M |
|
|
SLNO
552
DELISTED
Soleno Therapeutics
SLNO
| $13.3M | 0.02% |
+287,456
| New | +$15.8M |
|
553
Texas Pacific Land
TPL
$26.9B
| $13.3M | 0.02% |
46,188
-1,830
| -4% | -$559K |
|
554
Allegion
ALLE
$13.5B
| $13.2M | 0.02% |
83,184
-2,832
| -3% | -$472K |
|
|
LOMA
555
Loma Negra
LOMA
$1.34B
| $13.2M | 0.02% |
1,019,991
-181,109
| -15% | -$1.93M |
|
556
Clorox
CLX
$12B
| $13.2M | 0.02% |
130,744
-3,710
| -3% | -$403K |
|
557
Devon Energy
DVN
$51.3B
| $13.1M | 0.02% |
358,897
+94,553
| +36% | +$3.3M |
|
558
Essential Utilities
WTRG
$11.5B
| $13M | 0.02% |
339,233
+154,062
| +83% | +$6.06M |
|
559
Codexis
CDXS
$158M
| $13M | 0.02% |
7,966,498
+3,874,436
| +95% | +$7.9M |
|
560
Chefs' Warehouse
CHEF
$4.31B
| $12.9M | 0.02% |
207,069
+33,810
| +20% | +$2.03M |
|
561
Corpay
CPAY
$25.7B
| $12.8M | 0.02% |
42,665
-1,120
| -3% | -$325K |
|
562
W.R. Berkley
WRB
$28.1B
| $12.8M | 0.02% |
182,865
-6,240
| -3% | -$460K |
|
|
SW
563
Smurfit Westrock
SW
$25.3B
| $12.7M | 0.02% |
329,643
+22
| +0% | +$839 |
|
564
Banco Santander Chile
BSAC
$16.1B
| $12.6M | 0.02% |
405,588
-306,485
| -43% | -$8.93M |
|
565
ICICI Bank
IBN
$107B
| $12.6M | 0.02% |
422,772
+20,229
| +5% | +$621K |
|
566
Archer Daniels Midland
ADM
$38.7B
| $12.6M | 0.02% |
219,039
-817
| -0.4% | -$48.8K |
|
567
Geron
GERN
$898M
| $12.6M | 0.02% |
9,527,083
+3,556,160
| +60% | +$4.46M |
|
568
Centene
CNC
$30.5B
| $12.6M | 0.02% |
305,302
+3,309
| +1% | +$124K |
|
569
Textron
TXT
$14.7B
| $12.4M | 0.02% |
142,221
-169
| -0.1% | -$14.1K |
|
570
Darden Restaurants
DRI
$24.3B
| $12.4M | 0.02% |
67,238
+164
| +0.2% | +$29.9K |
|
571
Markel Group
MKL
$25.2B
| $12.4M | 0.02% |
5,746
-14
| -0.2% | -$28.4K |
|
572
Sea Limited
SE
$66.4B
| $12.3M | 0.02% |
96,719
-10,280
| -10% | -$1.52M |
|
573
Omnicom Group
OMC
$22.7B
| $12.3M | 0.02% |
152,710
+7,625
| +5% | +$583K |
|
574
Amcor
AMCR
$21.2B
| $12.3M | 0.02% |
295,172
+5,501
| +2% | +$227K |
|
575
SS&C Technologies
SSNC
$18.9B
| $12.3M | 0.02% |
140,643
-310
| -0.2% | -$26.4K |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.